Product News

Share this article:

FDA OK'd a new indication for Eli Lilly's Symbyax, a Zyprexa and Prozac combination therapy. Symbyax is now indicated for patients with treatment-resistant depression, in addition to its prior indication for bipolar depression.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions